Online inquiry

IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ783MR)

This product GTTS-WQ783MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ783MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12913MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ5944MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ811MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ3949MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ15963MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ605MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ15884MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ1406MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW